{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-000857","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.267840+00:00","generated_at":"2026-05-24T15:44:13.505452+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Entera Bio-OPKO collaboration: oral GLP-1/glucagon tablet, $8M equity investment","bullets":["OPKO purchased 3,685,226 Entera shares at ~$2.17/share ($8M) to fund Entera's 40% development cost share through Phase 1.","Profit/cost split initially 60% OPKO / 40% Entera; opt-out after Phase 1 yields 85%/15% with OPKO funding.","Parties expect to file IND with FDA later in 2025 for oral tablet combining OPK-88006 and Entera's N-Tab™ technology.","OPKO subject to 12-month lockup on shares and 24-month standstill on acquiring additional Entera equity.","Preclinical data reported September 2024 showed favorable pharmacodynamic and pharmacokinetic profiles."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-000857","json":"https://secwatch.observer/filing/0001178913-25-000857.json","markdown":"https://secwatch.observer/filing/0001178913-25-000857.md","text":"https://secwatch.observer/filing/0001178913-25-000857.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891325000857/0001178913-25-000857-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891325000857/zk2532871.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T15:44:13.505452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}